Actively Recruiting
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Led by Huai'an First People's Hospital · Updated on 2024-03-25
34
Participants Needed
1
Research Sites
292 weeks
Total Duration
On this page
Sponsors
H
Huai'an First People's Hospital
Lead Sponsor
Z
Zhenjiang First People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.
CONDITIONS
Official Title
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years old
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of at least 3 months
- No severe heart, lung, liver, or kidney disease as defined by specified clinical measures
- No significant contraindications to chemotherapy as determined by the physician
- Ability to understand and willingness to sign informed consent form
You will not qualify if you...
- Presence of other malignancies
- Cardiac vascular intervention or stent placement within 12 months, or history of significant cardiac disease such as myocardial infarction or unstable angina
- Uncontrolled active infection or visceral bleeding
- Pregnancy or lactation
- Participation in any other clinical study within 3 months prior to informed consent
- Any other condition considered unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital）
Huai'an, Jiangsu, China, 210000
Actively Recruiting
Research Team
S
Shandong Tao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here